Section Arrow
Quote
CTXR.NASDAQ
- Citius Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/01/07 16:04 EST
After Hours
Last
 0.9248
0 (0.00%)
Bid
0.9155
Ask
0.9383
High 0.93 
Low 0.924 
Volume 2.58K 
Regular Hours (Closed)
Last
 0.9248
-0.0552 (-5.63%)
Day High 
0.9716 
Prev. Close
0.98 
1-M High
1.2499 
Volume 
228.75K 
Bid
0.9155
Ask
0.9383
Day Low
0.8924 
Open
0.9667 
1-M Low
0.63 
Market Cap 
20.35M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.89 
20-SMA 1 
50-SMA 1.17 
52-W High 3.99 
52-W Low 0.63 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.38/2.23
Enterprise Value
21.07M
Balance Sheet
Book Value Per Share
3.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1316+0.0266+25.33%-- 
After Hours 0.136 +0.0104 +8.28%
ERASErasca5.425+1.795+49.45%-- 
After Hours 4.49 -0.68 -13.15%
RXRXRecursion Pharmaceuticals4.885+0.335+7.36%-- 
After Hours 4.86 +0.01 +0.21%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.73 0 0.00%
GLUEMonte Rosa Therapeutics23.3816+7.3716+46.04%54.09PE
After Hours 22.85 -0.43 -1.85%
Industry overview quotes are at least 15 minutes delayed
Business Description
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.